Ceramide as a Mediator of Non-Alcoholic Fatty Liver Disease and Associated Atherosclerosis
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Cardiovascular disease (CVD) is a serious comorbidity in nonalcoholic fatty liver disease (NAFLD). Since plasma ceramides are increased in NAFLD and sphingomyelin, a ceramide metabolite, is an independent risk factor for CVD, the role of ceramides in dyslipidemia was assessed using LDLR(-/-) mice, a diet-induced model of NAFLD and atherosclerosis. Mice were fed a standard or Western diet (WD), with or without myriocin, an inhibitor of ceramide synthesis. Hepatic and plasma ceramides were profiled and lipid and lipoprotein kinetics were quantified. Hepatic and intestinal expression of genes and proteins involved in insulin, lipid and lipoprotein metabolism were also determined. WD caused hepatic oxidative stress, inflammation, apoptosis, increased hepatic long-chain ceramides associated with apoptosis (C16 and C18) and decreased very-long-chain ceramide C24 involved in insulin signaling. The plasma ratio of ApoB/ApoA1 (proteins of VLDL/LDL and HDL) was increased 2-fold due to increased ApoB production. Myriocin reduced hepatic and plasma ceramides and sphingomyelin, and decreased atherosclerosis, hepatic steatosis, fibrosis, and apoptosis without any effect on oxidative stress. These changes were associated with decreased lipogenesis, ApoB production and increased HDL turnover. Thus, modulation of ceramide synthesis may lead to the development of novel strategies for the treatment of both NAFLD and its associated atherosclerosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATION
Bligh, E. G., & Dyer, W. J. (1959) · Canadian Journal of Biochemistry and Physiology · doi:10.1139/o59-099 · Cited by 54,751
A Receptor-Mediated Pathway for Cholesterol Homeostasis
Brown, M. S., & Goldstein, J. L. (1986) · Science · doi:10.1126/science.3513311 · Cited by 5,703 · cited 1×
“Thus, a defect in VLDLmetabolism initiates higher levels of remnant particles and lower levels of HDLcholesterol (HDLc), which are risk factors of atherosclerosis [4].”
BackgroundIntestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease
Jiang, C., Xie, C., Li, F., Zhang, L., Nichols, R. G., Krausz, K. W., Cai, J., Qi, Y., Fang, Z.-Z., Takahashi, S., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci76738 · Cited by 693
Levy, M., & Futerman, A. H. (2010) · IUBMB Life · doi:10.1002/iub.319 · Cited by 632 · cited 1×
“Distinct ceramide species are synthesized in mammals by a family of six ceramide synthases (CerS1-6) [47].”
BackgroundRapp, J. H., Lespine, A., Hamilton, R. L., Colyvas, N., Chaumeton, A. H., Tweedie-Hardman, J., Kotite, L., Kunitake, S. T., Havel, R. J., & Kane, J. P. (1994) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.14.11.1767 · Cited by 340
The metabolism and anti-atherogenic properties of HDL
Rye, K.-A., Bursill, C. A., Lambert, G., Tabet, F., & Barter, P. J. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r800034-jlr200 · Cited by 331
Sphingolipids and insulin resistance: the five Ws
Summers, S. A. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283373b66 · Cited by 136
Cited by
Sphingolipids and their metabolism in physiology and disease
Hannun, Y. A., & Obeid, L. M. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.107 · Cited by 2,051
Ceramides – Lipotoxic Inducers of Metabolic Disorders
Chaurasia, B., & Summers, S. A. (2015) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2015.07.006 · Cited by 616
Molecular pathways of nonalcoholic fatty liver disease development and progression
Bessone, F., Razori, M. V., & Roma, M. G. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2947-0 · Cited by 610
Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease
Mota, M., Banini, B. A., Cazanave, S. C., & Sanyal, A. J. (2016) · Metabolism · doi:10.1016/j.metabol.2016.02.014 · Cited by 570
The Subtle Balance between Lipolysis and Lipogenesis: A Critical Point in Metabolic Homeostasis
Saponaro, C., Gaggini, M., Carli, F., & Gastaldelli, A. (2015) · Nutrients · doi:10.3390/nu7115475 · Cited by 529
Kim, Y.-R., Lee, E.-J., Shin, K.-O., Kim, M. H., Pewzner-Jung, Y., Lee, Y.-M., Park, J.-W., Futerman, A. H., & Park, W.-J. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0340-1 · Cited by 474
Sphingolipids and phospholipids in insulin resistance and related metabolic disorders
Meikle, P. J., & Summers, S. A. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.169 · Cited by 423
Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies
Musso, G., Cassader, M., & Gambino, R. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.3 · Cited by 412
Ceramides and other sphingolipids as drivers of cardiovascular disease
Choi, R. H., Tatum, S. M., Symons, J. D., Summers, S. A., & Holland, W. L. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00536-1 · Cited by 387
Ceramides in Metabolism: Key Lipotoxic Players
Chaurasia, B., & Summers, S. A. (2021) · Annual Review of Physiology · doi:10.1146/annurev-physiol-031620-093815 · Cited by 343
Musso, G., Cassader, M., Paschetta, E., & Gambino, R. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.06.031 · Cited by 332
Beyond adiponectin and leptin: adipose tissue-derived mediators of inter-organ communication
Funcke, J.-B., & Scherer, P. E. (2019) · Journal of Lipid Research · doi:10.1194/jlr.r094060 · Cited by 327
Metabolic Messengers: ceramides
Summers, S. A., Chaurasia, B., & Holland, W. L. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0134-8 · Cited by 299
Kakazu, E., Mauer, A. S., Yin, M., & Malhi, H. (2016) · Journal of Lipid Research · doi:10.1194/jlr.m063412 · Cited by 280
Hypoxia-induced signaling in the cardiovascular system: pathogenesis and therapeutic targets
Zhao, Y., Xiong, W., Li, C., Zhao, R., Lu, H., Song, S., Zhou, Y., Hu, Y., Shi, B., & Ge, J. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01652-9 · Cited by 249
“470,471 An inhibitory effect of ceramide on hepatic cholesterol elimination, achieved through the suppression of hepatic Cyp7a1 and Abcg5/8 , was observed.”
BackgroundSphingolipids and Lipoproteins in Health and Metabolic Disorders
Iqbal, J., Walsh, M. T., Hammad, S. M., & Hussain, M. M. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2017.03.005 · Cited by 237
Rosqvist, F., Kullberg, J., Ståhlman, M., Cedernaes, J., Heurling, K., Johansson, H.-E., Iggman, D., Wilking, H., Larsson, A., Eriksson, O., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00160 · Cited by 237
Review: Enhancing gastrointestinal health in dairy cows
Plaizier, J. C., Danesh Mesgaran, M., Derakhshani, H., Golder, H., Khafipour, E., Kleen, J. L., Lean, I., Loor, J., Penner, G., & Zebeli, Q. (2018) · Animal · doi:10.1017/s1751731118001921 · Cited by 235
“From a mechanistic standpoint, blocking elongation and desaturation could lead to ceramide production and trigger inflammation (Kasumov et al., 2015).”
BackgroundNew Aspects of Lipotoxicity in Nonalcoholic Steatohepatitis
Mendez-Sanchez, N., Cruz-Ramon, V. C., Ramirez-Perez, O. L., Hwang, J. P., Barranco-Fragoso, B., & Cordova-Gallardo, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19072034 · Cited by 172
“Hepatocyte apoptosis induced by saturated FFAs was found to be ceramide independent, whereas in pancreatic β-cells, ceramides are important mediators of cellular failure and apoptosis and may function as a second messenger in cross-talk between the ER and mitochondria [56].”
BackgroundTargeting acid ceramidase inhibits YAP/TAZ signaling to reduce fibrosis in mice
Alsamman, S., Christenson, S. A., Yu, A., Ayad, N. M. E., Mooring, M. S., Segal, J. M., Hu, J. K.-H., Schaub, J. R., Ho, S. S., Rao, V., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay8798 · Cited by 122
Somm, E., Montandon, S. A., Loizides-Mangold, U., Gaïa, N., Lazarevic, V., De Vito, C., Perroud, E., Bochaton-Piallat, M.-L., Dibner, C., Schrenzel, J., et al. (2021) · Translational Research · doi:10.1016/j.trsl.2020.07.008 · Cited by 118
“Myriocin, an inhibitor of ceramide synthesis, reduced C16 and C24 ceramides in mice fed a western diet, improving several metabolic parameters including liver fibrosis.(64) To our knowledge, the effect of GLP-1Ra on hepatic ceramide accumulation has not been previously reported.”
BackgroundSpaceflight Activates Autophagy Programs and the Proteasome in Mouse Liver
Blaber, E., Pecaut, M., & Jonscher, K. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102062 · Cited by 70
The interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease
Finney, A. C., Das, S., Kumar, D., McKinney, M. P., Cai, B., Yurdagul, A., & Rom, O. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1116861 · Cited by 40
Pharmacological treatment of MASLD: contemporary treatment and future perspectives
Drygalski, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136518 · Cited by 39
Mucinski, J. M., Manrique‐Acevedo, C., Kasumov, T., Garrett, T. J., Gaballah, A., & Parks, E. J. (2020) · Lipids · doi:10.1002/lipd.12244 · Cited by 27
Self-citationMucinski, J. M., McCaffrey, J. M., Rector, R. S., Kasumov, T., & Parks, E. J. (2023) · Journal of Lipid Research · doi:10.1016/j.jlr.2023.100366 · Cited by 5
“supporting CERs in contributing to metabolic diseases such as type 2 diabetes, nonalcoholic fatty liver disease, and cardiovascular disease (21, 23, 24, 55), deeper knowledge of in vivo CER biology is needed.”
BackgroundSelf-citation
Metadata
- Authors
- Kasumov, T., Li, L., Li, M., Gulshan, K., Kirwan, J. P., Liu, X., Previs, S., Willard, B., Smith, J. D., & McCullough, A.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-05-20
- Volume
- 10
- Issue
- 5
- Pages
- e0126910
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W1530661366
- Cited by
- 209
- References
- 7
- FWCI
- 7.85
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.